newsfilter
← Latest News
PR Newswire·

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene...